NASDAQ: ETNB89bio Inc Stock
$8.88-0.28 (-3.06%)
Updated Apr 18, 2024
ETNB Price
$8.88
Fair Value Price
$4.06
Market Cap
$830.29M
52 Week Low
$6.58
52 Week High
$22.93
P/E
-4.44x
P/B
1.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$142.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$129M
Beta
0.92
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ETNB Overview
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ETNB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ETNB ($8.88) is overvalued by 118.65% relative to our estimate of its Fair Value price of $4.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ETNB ($8.88) is not significantly undervalued (118.65%) relative to our estimate of its Fair Value price of $4.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ETNB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ETNB due diligence checks available for Premium users.
Be the first to know about important ETNB news, forecast changes, insider trades & much more!
ETNB News
Valuation
ETNB fair value
Fair Value of ETNB stock based on Discounted Cash Flow (DCF)
Price
$8.88
Fair Value
$4.06
Overvalued by
118.65%
ETNB ($8.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ETNB ($8.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ETNB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ETNB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.44x
Industry
15.68x
Market
41.33x
ETNB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.55x
Industry
5.76x
ETNB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ETNB's financial health
Profit margin
Revenue
$0.0
Net Income
-$40.2M
Profit Margin
0%
ETNB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$596.3M
Liabilities
$60.0M
Debt to equity
0.11
ETNB's short-term assets ($593.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ETNB's short-term assets ($593.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ETNB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ETNB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.3M
Investing
-$63.6M
Financing
$162.2M
ETNB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ETNB vs Biotech Stocks
89bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.